Collegium Pharmaceutical Management
Management criteria checks 4/4
Collegium Pharmaceutical's CEO is Mike Heffernan, appointed in Jan 2002, has a tenure of 22.42 years. directly owns 0.086% of the company’s shares, worth $890.04K. The average tenure of the management team and the board of directors is 4.8 years and 10.3 years respectively.
Key information
Mike Heffernan
Chief executive officer
US$330.6k
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 22.4yrs |
| CEO ownership | 0.09% |
| Management average tenure | 4.8yrs |
| Board average tenure | 10.3yrs |
Recent management updates
Recent updates
Collegium Pharmaceutical (NASDAQ:COLL) Seems To Use Debt Quite Sensibly
Jun 05
Collegium Pharmaceutical: Some Positives From Its Quarterly 'Miss'
May 13It Looks Like Shareholders Would Probably Approve Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) CEO Compensation Package
May 10Collegium Pharmaceutical Q4: The Beat Goes On
Feb 26These 4 Measures Indicate That Collegium Pharmaceutical (NASDAQ:COLL) Is Using Debt Reasonably Well
Feb 24There's No Escaping Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Muted Revenues
Jan 05Here's Why Collegium Pharmaceutical (NASDAQ:COLL) Can Manage Its Debt Responsibly
Nov 12Is Collegium Pharmaceutical (NASDAQ:COLL) Using Too Much Debt?
Aug 09Is Collegium Pharmaceutical (NASDAQ:COLL) A Risky Investment?
Mar 10Is Collegium Pharmaceutical (NASDAQ:COLL) Using Too Much Debt?
Oct 18Collegium Pharmaceutical (NASDAQ:COLL) Has A Somewhat Strained Balance Sheet
Jun 24Collegium Pharmaceutical: Oversold And Cheap
Jun 12Collegium Pharmaceutical: Thoughts After Another Strategic Move
Feb 20There Is A Reason Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Price Is Undemanding
Feb 15We Think Collegium Pharmaceutical (NASDAQ:COLL) Can Stay On Top Of Its Debt
Oct 30CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | US$93m |
| Dec 31 2023 | US$331k | n/a | US$48m |
| Sep 30 2023 | n/a | n/a | US$9m |
| Jun 30 2023 | n/a | n/a | -US$11m |
| Mar 31 2023 | n/a | n/a | -US$29m |
| Dec 31 2022 | US$334k | n/a | -US$25m |
| Sep 30 2022 | n/a | n/a | -US$43m |
| Jun 30 2022 | n/a | n/a | -US$35m |
| Mar 31 2022 | n/a | n/a | US$43m |
| Dec 31 2021 | US$353k | n/a | US$72m |
| Sep 30 2021 | n/a | n/a | US$104m |
| Jun 30 2021 | n/a | n/a | US$107m |
| Mar 31 2021 | n/a | n/a | US$42m |
| Dec 31 2020 | US$304k | n/a | US$27m |
| Sep 30 2020 | n/a | n/a | US$18m |
| Jun 30 2020 | n/a | n/a | US$198k |
| Mar 31 2020 | n/a | n/a | -US$13m |
| Dec 31 2019 | US$251k | n/a | -US$23m |
| Sep 30 2019 | n/a | n/a | -US$11m |
| Jun 30 2019 | n/a | n/a | -US$22m |
| Mar 31 2019 | n/a | n/a | -US$30m |
| Dec 31 2018 | US$5m | US$317k | -US$39m |
| Sep 30 2018 | n/a | n/a | -US$66m |
| Jun 30 2018 | n/a | n/a | -US$62m |
| Mar 31 2018 | n/a | n/a | -US$70m |
| Dec 31 2017 | US$3m | US$547k | -US$75m |
Compensation vs Market: Mike's total compensation ($USD330.61K) is below average for companies of similar size in the US market ($USD3.37M).
Compensation vs Earnings: Mike's compensation has been consistent with company performance over the past year.
CEO
Mike Heffernan (60 yo)
22.4yrs
Tenure
US$330,614
Compensation
Mr. Michael Thomas Heffernan, also known as Mike, B.S. Pharm, R.Ph. serve as Independent Director at K36 Therapeutics, Inc. He serves as Lead Independent Director at Biohaven Ltd. since September 2022.Mr....
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 22.4yrs | US$330.61k | 0.086% $ 890.0k | |
| Executive VP & CFO | 3.1yrs | US$2.73m | 0.060% $ 626.0k | |
| Executive VP | 6.3yrs | US$2.87m | 0.062% $ 642.3k | |
| Executive VP & Chief Commercial Officer | 5.9yrs | US$2.61m | 0% $ 0 | |
| Executive VP & Chief Medical Officer | 2.3yrs | US$2.04m | 0.028% $ 292.8k | |
| Vice President of Investor Relations | no data | no data | no data | |
| Executive Vice President of Strategy & Corporate Development | 4.8yrs | no data | no data | |
| Head of Technical Operations | 2.7yrs | no data | no data |
4.8yrs
Average Tenure
52yo
Average Age
Experienced Management: COLL's management team is considered experienced (4.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 20.7yrs | US$330.61k | 0.086% $ 890.0k | |
| Independent Director | 10.3yrs | US$298.61k | 0.21% $ 2.2m | |
| Independent Director | 9.4yrs | US$299.61k | 0.0072% $ 74.7k | |
| Lead Independent Director | 11.9yrs | US$322.61k | 0.078% $ 808.0k | |
| Scientific Advisor | no data | no data | no data | |
| Scientific Advisor | no data | no data | no data | |
| Scientific Advisor | no data | no data | no data | |
| Scientific Advisor | no data | no data | no data | |
| Independent Director | 8yrs | US$289.61k | 0.11% $ 1.2m | |
| Scientific Advisor | no data | no data | no data | |
| Scientific Advisor | no data | no data | no data | |
| Scientific Advisor | no data | no data | no data |
10.3yrs
Average Tenure
70yo
Average Age
Experienced Board: COLL's board of directors are seasoned and experienced ( 10.3 years average tenure).